港A兩市輔助生殖板塊高開 杭州將部分“試管嬰兒”項目納入保障責任
格隆匯11月28日丨輔助生殖板塊高開,港股方面,錦欣生殖高開超7%,貝康醫療高開超4%;A股方面,漢商集團、達嘉維康、麥迪科技高開超5%,康芝藥業、悦心健康等高開。杭州西湖益聯保共保體將輔助生育部分項目納入保障責任,在2023年度實施輔助生育的參保市民,將可獲得最高3000元的報銷。實施定向補助後,參保人的胚胎培養和胚胎移植費用大部分將由“西湖益聯保”承擔。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.